Evidence map›Paper›PMID 39758259›Full record

ReviewDigital health

Artificial intelligence in precision medicine for lung cancer: A bibliometric analysis.

Yuchai Wang, Weilong Zhang, Xiang Liu, Li Tian, Wenjiao Li, Peng He, Sheng Huang, Fuyuan He, Xue Pan

Abstract readReview
In one paragraph

Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuchai WangDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.ORCID https://orcid.org/0009-0003-6851-8113
Weilong ZhangDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Xiang LiuDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Li TianDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Wenjiao LiDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Peng HeDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Sheng HuangDepartment of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Fuyuan HeSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.
Xue PanSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan Province, China.ORCID https://orcid.org/0009-0004-6324-6398

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The increasing body of evidence has been stimulating the application of artificial intelligence (AI) in precision medicine research for lung cancer. This trend necessitates a comprehensive overview of the growing number of publications to facilitate researchers' understanding of this field. Method: The bibliometric data for the current analysis was extracted from the Web of Science Core Collection database, CiteSpace, VOSviewer ,and an online website were applied to the analysis. Results: After the data were filtered, this search yielded 4062 manuscripts. And 92.27% of the papers were published from 2014 onwards. The main contributing countries were China, the United States, India, Japan, and Korea. These publications were mainly published in the following scientific disciplines, including Radiology Nuclear Medicine, Medical Imaging, Oncology, and Computer Science Notably, Li Weimin and Aerts Hugo J. W. L. stand out as leading authorities in this domain. In the keyword co-occurrence and co-citation cluster analysis of the publication, the knowledge base was divided into four clusters that are more easily understood, including screening, diagnosis, treatment, and prognosis. Conclusion: This bibliometric study reveals deep learning frameworks and AI-based radiomics are receiving attention. High-quality and standardized data have the potential to revolutionize lung cancer screening and diagnosis in the era of precision medicine. However, the importance of high-quality clinical datasets, the development of new and combined AI models, and their consistent assessment for advancing research on AI applications in lung cancer are highlighted before current research can be effectively applied in clinical practice.

Indexed as

artificial intelligencebibliometric analysishotspotsknowledge baseLung cancer

Identifiers

PMID39758259
PMCPMC11696962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.